Tatiana Prowell: Ribociclib is now FDA-approved for stage 2 and 3 hormone receptor positive, HER2 negative breast cancer
Erika Hamilton shared on X by Tatiana Prowell, additing:
”Well isn’t this a gift for a Tuesday! Welcome our 2nd CDK4/6 approved in the adj setting.
Remember with ribociclib: 3 yrs vs. 2 like abemaincludes intermediate risk pts including N0 intermittent vs. continues dosing neutropenia.”
Quoting Tatiana Prowell post on X:
”Ribociclib is now FDA-approved for treatment of adults with stage 2 and 3 hormone receptor positive, HER2 negative breast cancer at high risk of recurrence based on efficacy and safety results of the NATALEE trial.”
Source: Erika Hamilton/X and Tatiana Prowell/X
Erika Hamilton is a medical oncologist and the Director of Breast Cancer Program at Sarah Cannon Research Institute (USA). Dr. Hamilton is a past chair of ASCO’s Scientific Breast Committee ’21-’22, participant of the ASCO Leadership Development Program, Associate Editor for Clinical Breast Cancer, co-chair for Great Debates and Updates in Women’s Oncology Conference and a board member of the Susan G. Komen Foundation of Central Tennessee.
She is active in the community, volunteering with Gilda’s Club Middle Tennessee, the American Cancer Society’s Hope Lodge, Ovarcome ovarian cancer support organization, Brentwood Baptist Church and the Susan G. Komen Race for the Cure.
Tatiana M. Prowell is an Associate Professor of Oncology in the Division of Women’s Malignancies at the Johns Hopkins Kimmel Comprehensive Cancer Center and Breast Cancer Scientific Liaison to the U.S. Food and Drug Administration.
She was the principal architect of FDA’s policy on accelerated approval using pathological complete response as a novel regulatory endpoint in the neoadjuvant high-risk breast cancer setting, and a member of the Biden Cancer Moonshot Blue Ribbon Panel Cancer Immunology Working Group. A frequent public speaker, she is a three-time recipient of FDA’s Excellence in Communication Award.
She is a past Giants of Cancer Care Award finalist, the recipient of the 2019 John and Samuel Bard Medal in Science or Medicine, and the recipient of a 2020 Webby Special Achievement Award for her effective use of social media during the pandemic. A passionate medical educator and mentor, she was Chair of the 2020 ASCO Annual Meeting Education Committee.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023